Healthcare -
Biotechnology - NASDAQ - US
$ 3.55
-3.01 %
$ 319 M
Market Cap
-3.78
P/E
1. INTRINSIC VALUE
Balance Sheet
Chimerix, Inc.
| Current Assets | 189 M |
| Cash & Short-Term Investments | 183 M |
| Receivables | 1.14 M |
| Other Current Assets | 5.14 M |
| Non-Current Assets | 23.7 M |
| Long-Term Investments | 21.7 M |
| PP&E | 1.71 M |
| Other Non-Current Assets | 301 K |
| Current Liabilities | 18.4 M |
| Accounts Payable | 2.85 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 15.6 M |
| Non-Current Liabilities | 1.3 M |
| Long-Term Debt | 1.3 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Chimerix, Inc.
| Revenue | 324 K |
| Cost Of Revenue | 0 |
| Gross Profit | 324 K |
| Operating Expenses | 93.4 M |
| Operating Income | -93.1 M |
| Other Expenses | -11 M |
| Net Income | -82.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Chimerix, Inc.
| Net Income | -82.1 M |
| Depreciation & Amortization | 1 K |
| Capital Expenditures | -89 K |
| Stock-Based Compensation | 17.5 M |
| Change in Working Capital | 2.42 M |
| Others | -3.43 M |
| Free Cash Flow | -69.2 M |
Wall Street Analysts Price Targets
Chimerix, Inc.
CMRX has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CMRX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Chimerix, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.06 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
6.61 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
5 months ago
Aug 08, 2024
|
Sell 1.06 K
USD
|
Andriole Michael T.
PRESIDENT AND CEO
|
- 1285
|
0.8285 USD |
|
11 months ago
Feb 14, 2024
|
Sell 1.81 K
USD
|
Andriole Michael T.
PRESIDENT AND CEO
|
- 1744
|
1.0375 USD |
|
11 months ago
Feb 14, 2024
|
Sell 2.02 K
USD
|
LaSpaluto Michelle
CHIEF FINANCIAL OFFICER
|
- 1940
|
1.0426 USD |
|
11 months ago
Feb 14, 2024
|
Sell 2.78 K
USD
|
Jakeman David
VP OF FINANCE AND ACCOUNTING
|
- 2660
|
1.0439 USD |
|
1 year ago
Nov 17, 2023
|
Bought
16.5 K USD
|
MIDDLETON FRED A
Director
|
+ 17295
|
0.9553 USD |
|
1 year ago
Nov 10, 2023
|
Bought
2.49 K USD
|
MIDDLETON FRED A
Director
|
+ 2705
|
0.92 USD |
|
1 year ago
Sep 28, 2023
|
Sell 3.58 K
USD
|
Jakeman David
VP of Finance and Accounting
|
- 3610
|
0.9927 USD |
|
1 year ago
Sep 25, 2023
|
Bought
19.6 K USD
|
MIDDLETON FRED A
Director
|
+ 20000
|
0.9818 USD |
|
1 year ago
May 18, 2023
|
Bought
59.1 K USD
|
Andriole Michael T.
Chief Business Officer and CFO
|
+ 51700
|
1.1441 USD |
|
1 year ago
May 12, 2023
|
Bought
84.1 K USD
|
Sherman Michael A.
Chief Executive Officer
|
+ 75015
|
1.1214 USD |
|
1 year ago
May 12, 2023
|
Bought
13.5 K USD
|
Sherman Michael A.
Chief Executive Officer
|
+ 11985
|
1.1289 USD |
|
1 year ago
May 10, 2023
|
Bought
20 K USD
|
DEMSKI MARTHA J
Director
|
+ 18000
|
1.11 USD |
|
1 year ago
May 08, 2023
|
Bought
9.98 K USD
|
Meyer Robert J.
Director
|
+ 8750
|
1.14 USD |
|
1 year ago
Mar 28, 2023
|
Bought
24.2 K USD
|
MIDDLETON FRED A
Director
|
+ 20000
|
1.2076 USD |
|
1 year ago
Jan 26, 2023
|
Sell 5.69 K
USD
|
Jakeman David
Principal Accounting Officer
|
- 3230
|
1.7605 USD |
|
2 years ago
Sep 29, 2022
|
Bought
37.2 K USD
|
MIDDLETON FRED A
director:
|
+ 20000
|
1.8588 USD |
|
2 years ago
Sep 29, 2022
|
Sell 8.19 K
USD
|
Jakeman David
Principal Accounting Officer
|
- 4400
|
1.8603 USD |
|
2 years ago
May 19, 2022
|
Bought
40.7 K USD
|
MIDDLETON FRED A
director:
|
+ 20000
|
2.0369 USD |
|
2 years ago
May 19, 2022
|
Bought
2.91 K USD
|
Meyer Robert J.
director:
|
+ 1419
|
2.05 USD |
|
2 years ago
May 19, 2022
|
Bought
20.6 K USD
|
Meyer Robert J.
Director
|
+ 9981
|
2.06 USD |
|
2 years ago
May 17, 2022
|
Bought
25.6 K USD
|
Andriole Michael T.
Chief Business Officer and CFO
|
+ 15000
|
1.709 USD |
|
2 years ago
May 17, 2022
|
Bought
16.1 K USD
|
DEMSKI MARTHA J
director:
|
+ 10000
|
1.61 USD |
|
2 years ago
Feb 04, 2022
|
Sell 18.4 K
USD
|
Jakeman David
Principal Accounting Officer
|
- 3300
|
5.5622 USD |
|
3 years ago
Sep 30, 2021
|
Sell 28.4 K
USD
|
Jakeman David
Principal Accounting Officer
|
- 4590
|
6.19 USD |
|
3 years ago
Sep 14, 2021
|
Sell 37.4 M
USD
|
CANTEX PHARMACEUTICALS, INC.
10 percent owner
|
- 6500000
|
5.75 USD |
|
3 years ago
Jun 28, 2021
|
Bought
54.4 K USD
|
MIDDLETON FRED A
Director
|
+ 6950
|
7.83 USD |
|
3 years ago
Jun 25, 2021
|
Bought
23.7 K USD
|
MIDDLETON FRED A
Director
|
+ 3050
|
7.78 USD |
|
3 years ago
Apr 05, 2021
|
Sell 12.4 K
USD
|
Jakeman David
Principal Accounting Officer
|
- 1284
|
9.6786 USD |
|
3 years ago
Mar 01, 2021
|
Bought
14.7 K USD
|
Meyer Robert J.
Director
|
+ 1500
|
9.8 USD |
|
3 years ago
Jan 28, 2021
|
Sell 27.6 K
USD
|
Jakeman David
Principal Accounting Officer
|
- 3211
|
8.611 USD |
|
4 years ago
Oct 02, 2020
|
Sell 10.6 K
USD
|
Jakeman David
Principal Accounting Officer
|
- 4270
|
2.48 USD |
|
4 years ago
Aug 19, 2020
|
Bought
10.2 K USD
|
Meyer Robert J.
Director
|
+ 3500
|
2.92 USD |
|
4 years ago
Aug 10, 2020
|
Sell 5.15 K
USD
|
DEMSKI MARTHA J
Director
|
- 1584
|
3.2503 USD |
|
4 years ago
Aug 06, 2020
|
Sell 8.22 K
USD
|
DEMSKI MARTHA J
Director
|
- 2500
|
3.2895 USD |
|
4 years ago
Aug 07, 2020
|
Sell 8.12 K
USD
|
DEMSKI MARTHA J
Director
|
- 2500
|
3.25 USD |
|
4 years ago
Aug 04, 2020
|
Sell 16.2 K
USD
|
DEMSKI MARTHA J
Director
|
- 5000
|
3.25 USD |
|
4 years ago
Aug 05, 2020
|
Sell 8.19 K
USD
|
DEMSKI MARTHA J
Director
|
- 2500
|
3.2749 USD |
|
4 years ago
Mar 16, 2020
|
Bought
47.5 K USD
|
Andriole Michael T.
Chief Business Officer
|
+ 33300
|
1.4271 USD |
|
4 years ago
Mar 12, 2020
|
Bought
106 K USD
|
Sherman Michael A.
Chief Executive Officer
|
+ 72995
|
1.4474 USD |
|
4 years ago
Mar 12, 2020
|
Bought
106 K USD
|
Sherman Michael A.
Chief Executive Officer
|
+ 72995
|
1.4474 USD |
|
4 years ago
Mar 12, 2020
|
Bought
69.9 K USD
|
MIDDLETON FRED A
Director
|
+ 50000
|
1.398 USD |
|
4 years ago
Feb 07, 2020
|
Sell 4.34 K
USD
|
Nichols Garrett
Chief Medical Officer
|
- 2550
|
1.7 USD |
|
4 years ago
Feb 10, 2020
|
Sell 14.8 K
USD
|
Nichols Garrett
Chief Medical Officer
|
- 8805
|
1.6843 USD |
|
4 years ago
Feb 07, 2020
|
Sell 3.89 K
USD
|
Jakeman David
Principal Accounting Officer
|
- 2290
|
1.7 USD |
|
5 years ago
Jan 07, 2020
|
Sell 66 K
USD
|
Nichols Garrett
Chief Medical Officer
|
- 30680
|
2.1527 USD |
|
5 years ago
Nov 13, 2019
|
Bought
54.6 K USD
|
MIDDLETON FRED A
Director
|
+ 30000
|
1.8189 USD |
|
5 years ago
Nov 11, 2019
|
Bought
33.2 K USD
|
MIDDLETON FRED A
Director
|
+ 20000
|
1.6595 USD |
|
5 years ago
Nov 06, 2019
|
Bought
156 K USD
|
Andriole Michael T.
Chief Business Officer
|
+ 100000
|
1.56 USD |
|
5 years ago
Nov 06, 2019
|
Bought
15.8 K USD
|
Meyer Robert J.
Director
|
+ 10000
|
1.5797 USD |
|
5 years ago
May 28, 2019
|
Bought
64.8 K USD
|
DEMSKI MARTHA J
Director
|
+ 18000
|
3.6 USD |
|
5 years ago
May 20, 2019
|
Bought
104 K USD
|
Sherman Michael A.
Chief Executive Officer
|
+ 30000
|
3.4772 USD |
|
5 years ago
May 20, 2019
|
Bought
104 K USD
|
Sherman Michael A.
Chief Executive Officer
|
+ 30000
|
3.4772 USD |
|
5 years ago
May 10, 2019
|
Bought
87.7 K USD
|
MIDDLETON FRED A
Director
|
+ 30000
|
2.9226 USD |
|
6 years ago
Jun 12, 2018
|
Bought
45 K USD
|
Berrey M Michelle
President and CEO
|
+ 10000
|
4.5015 USD |
|
6 years ago
May 17, 2018
|
Sell 144 K
USD
|
MARIO ERNEST
Director
|
- 30000
|
4.7977 USD |
|
6 years ago
May 18, 2018
|
Sell 72.1 K
USD
|
MARIO ERNEST
Director
|
- 15000
|
4.8095 USD |
|
6 years ago
May 16, 2018
|
Sell 144 K
USD
|
MARIO ERNEST
Director
|
- 30000
|
4.7936 USD |
|
6 years ago
May 15, 2018
|
Sell 141 K
USD
|
MARIO ERNEST
Director
|
- 30000
|
4.6936 USD |
|
6 years ago
May 11, 2018
|
Sell 32.6 K
USD
|
MARIO ERNEST
Director
|
- 7143
|
4.5659 USD |
|
6 years ago
May 11, 2018
|
Sell 106 K
USD
|
MARIO ERNEST
Director
|
- 22857
|
4.6273 USD |
|
6 years ago
May 14, 2018
|
Sell 105 K
USD
|
MARIO ERNEST
Director
|
- 22553
|
4.666 USD |
|
6 years ago
May 10, 2018
|
Sell 12.9 K
USD
|
MARIO ERNEST
Director
|
- 2815
|
4.6 USD |
|
7 years ago
Dec 01, 2017
|
Sell 88.7 K
USD
|
Richardson Linda M
Chief Commercial Officer
|
- 19833
|
4.471 USD |
|
8 years ago
Dec 27, 2016
|
Sell 337 K
USD
|
MARIO ERNEST
Director
|
- 72073
|
4.6778 USD |
|
8 years ago
Dec 27, 2016
|
Sell 16.9 K
USD
|
MARIO ERNEST
Director
|
- 3636
|
4.65 USD |
|
8 years ago
Dec 28, 2016
|
Sell 18.7 K
USD
|
MARIO ERNEST
Director
|
- 4000
|
4.6707 USD |
|
8 years ago
Dec 28, 2016
|
Sell 91.6 K
USD
|
MARIO ERNEST
Director
|
- 20291
|
4.516 USD |
|
8 years ago
Sep 15, 2016
|
Sell 25.2 K
USD
|
LEONARD JOHN M.
Director
|
- 5000
|
5.0325 USD |
|
8 years ago
Aug 29, 2016
|
Bought
100 K USD
|
Berrey M Michelle
President and CEO
|
+ 22417
|
4.471 USD |
|
8 years ago
Jun 24, 2016
|
Bought
185 K USD
|
MARIO ERNEST
Director
|
+ 50000
|
3.6969 USD |
|
8 years ago
Jun 24, 2016
|
Bought
48.6 K USD
|
Berrey M Michelle
President and CEO
|
+ 13188
|
3.687 USD |
|
8 years ago
May 13, 2016
|
Bought
45.3 K USD
|
MARIO ERNEST
Director
|
+ 10000
|
4.5328 USD |
|
8 years ago
May 11, 2016
|
Bought
117 K USD
|
MARIO ERNEST
Director
|
+ 24200
|
4.8498 USD |
|
8 years ago
May 10, 2016
|
Bought
3.8 K USD
|
MARIO ERNEST
Director
|
+ 800
|
4.755 USD |
|
8 years ago
Mar 16, 2016
|
Bought
23.9 K USD
|
MARIO ERNEST
Director
|
+ 5000
|
4.7796 USD |
|
8 years ago
Mar 15, 2016
|
Bought
103 K USD
|
MARIO ERNEST
Director
|
+ 20000
|
5.1314 USD |
|
8 years ago
Mar 01, 2016
|
Bought
46.1 K USD
|
WOLLAEGER TIMOTHY
Director
|
+ 10000
|
4.61 USD |
|
8 years ago
Mar 01, 2016
|
Bought
48.9 K USD
|
DEMSKI MARTHA J
Director
|
+ 10000
|
4.89 USD |
|
9 years ago
Dec 29, 2015
|
Bought
70.8 K USD
|
Machado Clarence Patrick
Director
|
+ 10000
|
7.0846 USD |
|
9 years ago
Dec 29, 2015
|
Bought
887 K USD
|
MARIO ERNEST
Director
|
+ 125000
|
7.0929 USD |
|
9 years ago
Nov 02, 2015
|
Sell 3.91 K
USD
|
DEMSKI MARTHA J
Director
|
- 100
|
39.07 USD |
|
9 years ago
Nov 02, 2015
|
Sell 4.05 K
USD
|
DEMSKI MARTHA J
Director
|
- 100
|
40.49 USD |
|
9 years ago
Nov 02, 2015
|
Sell 38.6 K
USD
|
DEMSKI MARTHA J
Director
|
- 926
|
41.69 USD |
|
9 years ago
Oct 01, 2015
|
Sell 67.7 K
USD
|
DEMSKI MARTHA J
Director
|
- 1800
|
37.61 USD |
|
9 years ago
Oct 01, 2015
|
Sell 7.67 K
USD
|
DEMSKI MARTHA J
Director
|
- 200
|
38.35 USD |
|
9 years ago
Sep 01, 2015
|
Sell 75.1 K
USD
|
DEMSKI MARTHA J
Director
|
- 1562
|
48.1 USD |
|
9 years ago
Sep 01, 2015
|
Sell 21.2 K
USD
|
DEMSKI MARTHA J
Director
|
- 438
|
48.48 USD |
|
9 years ago
Aug 21, 2015
|
Bought
47.4 K USD
|
LEONARD JOHN M.
Director
|
+ 1000
|
47.38 USD |
|
9 years ago
Aug 03, 2015
|
Sell 109 K
USD
|
DEMSKI MARTHA J
Director
|
- 2000
|
54.6138 USD |
|
9 years ago
Jul 17, 2015
|
Sell 1.4 M
USD
|
Trost Timothy W.
SVP, CFO & Secretary
|
- 28000
|
50 USD |
|
9 years ago
Jul 01, 2015
|
Sell 59.4 K
USD
|
DEMSKI MARTHA J
Director
|
- 1300
|
45.7 USD |
|
9 years ago
Jul 01, 2015
|
Sell 32.6 K
USD
|
DEMSKI MARTHA J
Director
|
- 700
|
46.63 USD |
|
9 years ago
Jun 01, 2015
|
Sell 83.2 K
USD
|
DEMSKI MARTHA J
Director
|
- 2000
|
41.5821 USD |
|
9 years ago
May 12, 2015
|
Bought
75.2 K USD
|
Ricciardi Lisa
Director
|
+ 1950
|
38.54 USD |
|
9 years ago
May 01, 2015
|
Sell 69.4 K
USD
|
DEMSKI MARTHA J
Director
|
- 2000
|
34.71 USD |
|
9 years ago
Apr 01, 2015
|
Sell 62.5 K
USD
|
DEMSKI MARTHA J
Director
|
- 1700
|
36.78 USD |
|
9 years ago
Apr 01, 2015
|
Sell 11.2 K
USD
|
DEMSKI MARTHA J
Director
|
- 300
|
37.42 USD |
|
9 years ago
Mar 02, 2015
|
Sell 60 K
USD
|
DEMSKI MARTHA J
Director
|
- 1500
|
40 USD |
|
9 years ago
Mar 02, 2015
|
Sell 20.4 K
USD
|
DEMSKI MARTHA J
Director
|
- 500
|
40.7 USD |
|
9 years ago
Feb 02, 2015
|
Sell 76.8 K
USD
|
DEMSKI MARTHA J
Director
|
- 2000
|
38.3845 USD |
|
10 years ago
Jan 02, 2015
|
Sell 82.2 K
USD
|
DEMSKI MARTHA J
Director
|
- 2000
|
41.077 USD |
|
10 years ago
Nov 05, 2014
|
Bought
290 K USD
|
MARIO ERNEST
Director
|
+ 10000
|
29 USD |
|
10 years ago
Nov 05, 2014
|
Bought
116 K USD
|
LEONARD JOHN M.
Director
|
+ 4000
|
29 USD |
|
10 years ago
Sep 25, 2014
|
Sell 139 K
USD
|
Trost Timothy W.
Sr. Vice President and CFO
|
- 5000
|
27.7549 USD |
|
10 years ago
Aug 25, 2014
|
Sell 126 K
USD
|
Trost Timothy W.
Sr. Vice President and CFO
|
- 5000
|
25.1343 USD |
|
10 years ago
Sep 09, 2014
|
Sell 1.46 M
USD
|
NIEDEL JAMES
Director
|
- 51100
|
28.54 USD |
|
10 years ago
Sep 10, 2014
|
Sell 2.92 M
USD
|
NIEDEL JAMES
Director
|
- 97129
|
30.03 USD |
|
10 years ago
Sep 09, 2014
|
Sell 6.24 M
USD
|
NIEDEL JAMES
Director
|
- 217321
|
28.72 USD |
|
10 years ago
Sep 09, 2014
|
Sell 1.74 M
USD
|
NIEDEL JAMES
Director
|
- 58531
|
29.67 USD |
|
10 years ago
Sep 10, 2014
|
Sell 10.3 M
USD
|
NIEDEL JAMES
Director
|
- 347188
|
29.54 USD |
|
10 years ago
Sep 11, 2014
|
Sell 9.72 M
USD
|
NIEDEL JAMES
Director
|
- 328680
|
29.58 USD |
|
10 years ago
Sep 09, 2014
|
Sell 3.6 M
USD
|
WOLLAEGER TIMOTHY
director, 10 percent owner:
|
- 122950
|
29.2751 USD |
|
10 years ago
Sep 09, 2014
|
Sell 3.6 M
USD
|
Sanderling Venture Partners V, LP
10 percent owner
|
- 122950
|
29.2751 USD |
|
10 years ago
Sep 05, 2014
|
Sell 183 K
USD
|
Sanderling Venture Partners VI Co Investment Fund LP
10 percent owner
|
- 7735
|
23.6622 USD |
|
10 years ago
Sep 08, 2014
|
Sell 2.27 M
USD
|
Sanderling Venture Partners VI Co Investment Fund LP
10 percent owner
|
- 92265
|
24.6099 USD |
|
10 years ago
Sep 05, 2014
|
Sell 183 K
USD
|
WOLLAEGER TIMOTHY
director, 10 percent owner:
|
- 7735
|
23.6622 USD |
|
10 years ago
Sep 08, 2014
|
Sell 2.27 M
USD
|
WOLLAEGER TIMOTHY
director, 10 percent owner:
|
- 92265
|
24.6099 USD |
|
10 years ago
Sep 05, 2014
|
Bought
232 K USD
|
MARIO ERNEST
Director
|
+ 10000
|
23.1872 USD |
|
10 years ago
Aug 25, 2014
|
Sell 126 K
USD
|
Trost Timothy W.
Sr. Vice President and CFO
|
- 5000
|
25.1343 USD |
|
10 years ago
Jul 25, 2014
|
Sell 112 K
USD
|
Trost Timothy W.
See Remarks
|
- 5000
|
22.3524 USD |
|
10 years ago
Jun 25, 2014
|
Sell 114 K
USD
|
Trost Timothy W.
Sr. Vice President and CFO
|
- 5000
|
22.7394 USD |
|
10 years ago
May 27, 2014
|
Bought
142 K USD
|
MARIO ERNEST
Director
|
+ 10000
|
14.22 USD |
|
10 years ago
May 27, 2014
|
Sell 87.1 K
USD
|
Trost Timothy W.
SVP and CFO
|
- 5000
|
17.4134 USD |
|
10 years ago
May 27, 2014
|
Bought
200 K USD
|
Berrey M Michelle
See Remarks
|
+ 14065
|
14.22 USD |
|
10 years ago
Apr 25, 2014
|
Sell 93.3 K
USD
|
Trost Timothy W.
See Remarks
|
- 5000
|
18.665 USD |
|
10 years ago
Mar 25, 2014
|
Sell 127 K
USD
|
Trost Timothy W.
Sr. VP and CFO
|
- 5000
|
25.3725 USD |
|
10 years ago
Mar 13, 2014
|
Sell 474 K
USD
|
MOCH KENNETH I
President and CEO
|
- 18979
|
25 USD |
|
10 years ago
Feb 24, 2014
|
Sell 221 K
USD
|
MOCH KENNETH I
President and CEO
|
- 11072
|
20 USD |
|
10 years ago
Feb 25, 2014
|
Sell 96.5 K
USD
|
Trost Timothy W.
Sr. VP & CFO
|
- 5000
|
19.294 USD |
|
10 years ago
Jan 30, 2014
|
Sell 18.6 K
USD
|
MOCH KENNETH I
President and CEO
|
- 928
|
20 USD |
|
10 years ago
Jan 27, 2014
|
Sell 91.3 K
USD
|
Trost Timothy W.
Sr. Vice President and CFO
|
- 5000
|
18.2588 USD |
|
11 years ago
Dec 26, 2013
|
Sell 76.1 K
USD
|
Trost Timothy W.
Sr. VP and CFO
|
- 5000
|
15.2145 USD |
|
11 years ago
Dec 13, 2013
|
Bought
69.5 K USD
|
MARIO ERNEST
Director
|
+ 5000
|
13.9 USD |
|
11 years ago
Dec 09, 2013
|
Bought
14.4 K USD
|
DRAKE RODMAN L
Director
|
+ 1000
|
14.35 USD |
|
11 years ago
Nov 25, 2013
|
Sell 74.9 K
USD
|
Trost Timothy W.
SVP, CFO & Secretary
|
- 5000
|
14.9867 USD |
|
11 years ago
Nov 25, 2013
|
Bought
15 K USD
|
DRAKE RODMAN L
Director
|
+ 1000
|
15.0099 USD |
|
11 years ago
Nov 25, 2013
|
Bought
122 K USD
|
MARIO ERNEST
Director
|
+ 8000
|
15.2 USD |
|
11 years ago
Nov 22, 2013
|
Bought
6.98 K USD
|
DRAKE RODMAN L
Director
|
+ 449
|
15.55 USD |
|
11 years ago
Nov 20, 2013
|
Bought
765 USD
|
DRAKE RODMAN L
Director
|
+ 51
|
15 USD |
|
11 years ago
Nov 19, 2013
|
Bought
114 K USD
|
MARIO ERNEST
Director
|
+ 7500
|
15.25 USD |
|
11 years ago
Nov 15, 2013
|
Bought
265 USD
|
DRAKE RODMAN L
Director
|
+ 17
|
15.56 USD |
|
11 years ago
Nov 15, 2013
|
Bought
4.41 K USD
|
DRAKE RODMAN L
Director
|
+ 283
|
15.57 USD |
|
11 years ago
Nov 15, 2013
|
Bought
10.9 K USD
|
DRAKE RODMAN L
Director
|
+ 700
|
15.551 USD |
|
11 years ago
Nov 15, 2013
|
Sell 53.3 K
USD
|
Trost Timothy W.
SVP, CFO & Secretary
|
- 3409
|
15.6275 USD |
|
11 years ago
Nov 15, 2013
|
Sell 39 K
USD
|
MOCH KENNETH I
President and CEO
|
- 2500
|
15.6163 USD |
|
11 years ago
Oct 25, 2013
|
Sell 80.2 K
USD
|
Trost Timothy W.
Sr. Vice President and CFO
|
- 5000
|
16.0374 USD |
|
11 years ago
Oct 23, 2013
|
Sell 6.94 M
USD
|
CHAMPSI FARAH
Director
|
- 447499
|
15.51 USD |
|
11 years ago
Oct 23, 2013
|
Sell 10.5 M
USD
|
Hutton Wende S
director, 10 percent owner:
|
- 674771
|
15.51 USD |
|
11 years ago
Oct 23, 2013
|
Sell 3.36 M
USD
|
PAPPAS ARTHUR M
Director
|
- 216840
|
15.51 USD |
|
11 years ago
Oct 23, 2013
|
Sell 10.5 M
USD
|
Canaan VII L P
director, 10 percent owner:
|
- 674771
|
15.51 USD |
|
11 years ago
Oct 23, 2013
|
Sell 9.08 M
USD
|
NIEDEL JAMES
director, 10 percent owner:
|
- 585602
|
15.51 USD |
|
11 years ago
Oct 23, 2013
|
Sell 9.08 M
USD
|
New Leaf Ventures II, L.P.
Director
|
- 585602
|
15.51 USD |
|
11 years ago
Oct 23, 2013
|
Sell 9.08 M
USD
|
New Leaf Ventures II, L.P.
10 percent owner
|
- 585602
|
15.51 USD |
|
11 years ago
Aug 30, 2013
|
Bought
1.01 K USD
|
MARIO ERNEST
Director
|
+ 64
|
15.75 USD |
|
11 years ago
Aug 30, 2013
|
Bought
12.4 K USD
|
MARIO ERNEST
Director
|
+ 786
|
15.8 USD |
|
11 years ago
Aug 29, 2013
|
Bought
27.1 K USD
|
MARIO ERNEST
Director
|
+ 1714
|
15.8 USD |
|
11 years ago
Aug 29, 2013
|
Bought
39.6 K USD
|
MARIO ERNEST
Director
|
+ 2500
|
15.85 USD |
|
11 years ago
Aug 26, 2013
|
Bought
33.6 K USD
|
MARIO ERNEST
Director
|
+ 2000
|
16.8 USD |
|
11 years ago
Aug 26, 2013
|
Bought
34.6 K USD
|
MARIO ERNEST
Director
|
+ 2000
|
17.3 USD |
|
11 years ago
Aug 26, 2013
|
Bought
34.3 K USD
|
MARIO ERNEST
Director
|
+ 1960
|
17.5 USD |
|
11 years ago
Aug 23, 2013
|
Bought
104 K USD
|
Berrey M Michelle
Chief Medical Officer
|
+ 5540
|
18.7 USD |
|
11 years ago
Aug 20, 2013
|
Bought
700 USD
|
MARIO ERNEST
Director
|
+ 40
|
17.5 USD |
|
11 years ago
Aug 19, 2013
|
Bought
35 K USD
|
MARIO ERNEST
Director
|
+ 2000
|
17.5 USD |
|
11 years ago
Aug 16, 2013
|
Bought
34.9 K USD
|
MARIO ERNEST
Director
|
+ 2000
|
17.45 USD |
7. News
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility
globenewswire.com
- 2 weeks ago
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diffuse midline glioma bolster confidence in FDA approval, despite potential timeline uncertainties. Financially, CMRX has a cash runway of 6–7 quarters, sufficient to reach an FDA decision, but risks of dilution remain.
seekingalpha.com
- 1 month ago
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end.
globenewswire.com
- 1 month ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 385,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).
globenewswire.com
- 1 month ago
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX ) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O'Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen - Chief Scientific Officer Michelle LaSpaluto - Chief Financial Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen and welcome to the Chimerix Third Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor from Stern Investor Relations.
seekingalpha.com
- 2 months ago
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.
zacks.com
- 2 months ago
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview.
globenewswire.com
- 2 months ago
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).
globenewswire.com
- 3 months ago
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).
globenewswire.com
- 4 months ago
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago.
zacks.com
- 5 months ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).
globenewswire.com
- 6 months ago
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.
globenewswire.com
- 7 months ago
8. Profile
Summary
Chimerix, Inc. CMRX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 319 M
Dividend Yield
0.00%
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Contact
2505 Meridian Parkway, Durham, NC, 27713
https://www.chimerix.com
IPO
Date
April 11, 2013
Employees
72
Officers
Dr. Roy W. Ware M.B.A., Ph.D.
Chief Manufacturing Technology Officer
Ms. Michelle LaSpaluto
Chief Financial Officer
Dr. Joshua E. Allen Ph.D.
Chief Scientific Officer
Dr. Allen S. Melemed M.B.A., M.D.
Chief Medical Officer
Mr. David Jakeman CPA
Vice President of Accounting & Finance
Mr. Michael T. Andriole M.B.A.
Chief Executive Officer, President & Director
Mr. Thomas J. Riga
Chief Operating & Commercial Officer
Dr. Michael A. Alrutz J.D., Ph.D.
Senior Vice President, General Counsel & Corporate Secretary